Clinical Trial Update: TORI 104 Pre-Surgical Dasatinib [Phase 2]

View source ↗

Summary

A Phase 2 trial of pre-surgical dasatinib for breast cancer (TORI 104) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN